IDH1 and acute myeloid leukemia: Some of these inhibitors were also shown to be effective in clinical trials, and AG-221 (enasidenib) in 2017 and AG-120 (ivosidenib) in 2018 were approved by the FDA for treatment of relapsed or refractory AML with IDH2 or IDH1 mutations, respectively [42,43].